Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01850524
Registration number
NCT01850524
Ethics application status
Date submitted
26/04/2013
Date registered
9/05/2013
Date last updated
21/07/2023
Titles & IDs
Public title
IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Query!
Scientific title
A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma
Query!
Secondary ID [1]
0
0
2013-000326-54
Query!
Secondary ID [2]
0
0
C16014
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Multiple Myeloma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Other cancer types
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ixazomib
Treatment: Drugs - Placebo
Treatment: Drugs - Dexamethasone
Treatment: Drugs - Lenalidomide
Placebo Comparator: Placebo + LenDex - Participants who were randomly assigned to receive placebo matching capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib matching placebo capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
Active Comparator: Active Comparator: Ixazomib + LenDex - Participants who were randomly assigned to receive Ixazomib 4.0 mg capsule single oral dose on Days 1, 8 and 15 along with standard regimen of LenDex (lenalidomide 25 mg capsules orally on Days 1-21 and dexamethasone 40 mg tablets orally on Days 1, 8, 15 and 22) for the first 18 cycles (each cycle was of 28 days). Following Cycle 18, participants received 3.0 mg ixazomib capsule as single oral dose on Days 1, 8 and 15 along with lenalidomide 10 mg capsules orally on Days 1-21 in each 28-day cycle until progressive disease or unacceptable toxicity, whichever comes first up to end of study (up to approximately 109 months).
Treatment: Drugs: Ixazomib
IXAZOMIB capsules.
Treatment: Drugs: Placebo
IXAZOMIB matching-placebo capsules.
Treatment: Drugs: Dexamethasone
Dexamethasone tablets.
Treatment: Drugs: Lenalidomide
Lenalidomide capsules.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression Free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death due to any cause according to International Myeloma Working Group (IMWG) criteria whichever occurs first. PD required one of the following: Increase of >=25% from nadir in: Serum M-component and/or (the absolute increase must be >=0.5 g/dL); Urine M-component and/or (the absolute increase must be >=200 mg/24 hours); in participants without measurable serum and urine M-protein levels: the difference between involved and uninvolved free light chain (FLC) levels (absolute increase must be > 10 mg/dL); Bone marrow plasma cell percentage: the absolute % must be >10%; development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; hypercalcemia (corrected serum calcium > 11.5 mg/dL or 2.85 mmol/L).
Query!
Timepoint [1]
0
0
Up to approximately 79 months
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the time from the date of randomization to the date of death. Participants without documented death at the time of analysis are censored at the date last known to be alive.
Query!
Timepoint [1]
0
0
From the date of randomization to death due to any cause (Up to approximately 9 years)
Query!
Secondary outcome [2]
0
0
Complete Response (CR) Rate
Query!
Assessment method [2]
0
0
CR rate was defined as the percentage of participants who achieve CR assessed by an IRC relative to the intent-to-treat (ITT) population during the treatment period. Percentage of participants with CR, as assessed by IMWG disease assessment criteria were reported. CR was defined as negative immunofixation of serum and urine along with the disappearance of any soft tissue plasmacytomas and <5 % plasma cells (PC's) in bone marrow.
Query!
Timepoint [2]
0
0
Up to approximately 9 years
Query!
Secondary outcome [3]
0
0
Pain Response Rate as Assessed by the Brief Pain Inventory- Short Form (BPI-SF) and Analgesic Use
Query!
Assessment method [3]
0
0
Pain response rate was defined as percentage of participants with pain response. Pain response was defined as the occurrence of at least a 30% reduction from baseline in BPI-SF worst pain score over the last 24 hours without an increase in analgesic use for 2 consecutive measurements > 28 days apart, were reported. Brief Pain Inventory - Short Form (m-BPI-SF) is a participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable). Percentages are rounded off to the nearest single decimal.
Query!
Timepoint [3]
0
0
Up to approximately 9 years
Query!
Secondary outcome [4]
0
0
Overall Response Rate (ORR)
Query!
Assessment method [4]
0
0
ORR was defined as the percentage of participants who achieved CR + partial response (PR) + very good partial response (VGPR) (including sCR) or better relative to the ITT population during treatment period. CR was defined as negative immunofixation of serum and urine along with the disappearance of any soft tissue plasmacytomas and <5 % PC's in bone marrow. PR was defined as =50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by =90% along with =50% reduction in the size of soft tissue plasmacytomas. VGPR was defined as =90% in serum M-component plus urine M-component <100 mg/24. sCR is defined as stringent complete response. Percentages are rounded off to nearest whole numbers.
Query!
Timepoint [4]
0
0
Up to approximately 9 years
Query!
Secondary outcome [5]
0
0
Time to Response
Query!
Assessment method [5]
0
0
Time to response was defined as the time from the date of randomization to the first documentation of PR or better, as measured by IMWG criteria.
Query!
Timepoint [5]
0
0
Up to approximately 9 years
Query!
Secondary outcome [6]
0
0
Duration of Response
Query!
Assessment method [6]
0
0
Duration of response was measured as the time from the date of first documentation of PR or better to the date of first documented progression (PD) for responders, as measured by IMWG criteria.
Query!
Timepoint [6]
0
0
Up to approximately 9 years
Query!
Secondary outcome [7]
0
0
Time to Progression (TTP)
Query!
Assessment method [7]
0
0
Time to progression was defined as the time from randomization to the date of first documented disease progression.
Query!
Timepoint [7]
0
0
Up to approximately 9 years
Query!
Secondary outcome [8]
0
0
Progression Free Survival (PFS)-2
Query!
Assessment method [8]
0
0
PFS2 was defined as the time from the date of randomization to the date of documentation of disease progression on the subsequent line of anticancer therapy, as assessed by the investigator in accordance with IMWG criteria, or death due to any cause, whichever occurs first.
Query!
Timepoint [8]
0
0
Up to approximately 9 years
Query!
Secondary outcome [9]
0
0
Number of Participants With Shifts From Baseline to Worst Value in Eastern Cooperative Oncology Group (ECOG) Performance Score
Query!
Assessment method [9]
0
0
Eastern Cooperative Oncology Group (ECOG) scale score ranged from 0 to 5, where 0 indicated normal activity and 5 indicated death. The data is reported for those categories where at least 1 participant had worst post-baseline value for each ECOG score.
Query!
Timepoint [9]
0
0
Up to approximately 9 years
Query!
Secondary outcome [10]
0
0
Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [10]
0
0
An AE was any untoward medical occurrence in a participant administered a medicinal investigational drug. The untoward medical occurrence does not necessarily have to have a causal relationship with treatment. An SAE is any untoward medical occurrence that results in death; is life-threatening; requires inpatient hospitalization or prolongation of present hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect or is a medically important event that may not be immediately life-threatening or result in death or hospitalization, but may jeopardize the participant or may require intervention to prevent one of other outcomes listed in definition above, or involves suspected transmission via a medicinal product of an infectious agent.
Query!
Timepoint [10]
0
0
From the date of randomization through 30 days after the last dose of study drug up to end of study (up to approximately 9 years)
Query!
Secondary outcome [11]
0
0
Number of Participants With Abnormal Serum Chemistry and Hematology Laboratory Values Based on Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [11]
0
0
The laboratory values assessment included serum chemistry and hematology. The Serum chemistry assessment included blood urea nitrogen (BUN), creatinine, bilirubin (total), urate, lactate dehydrogenase, phosphate, albumin, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), glucose, sodium, potassium, calcium, chloride, carbon dioxide (CO2), magnesium, thyroid stimulating hormone (TSH). Hematology assessment included hemoglobin, hematocrit, platelet (count), leukocytes with differential neutrophils (ANC). Participants with abnormal serum chemistry laboratory values reported as TEAEs are reported. TEAEs were defined as events that occurred after administration of the first dose of any agent in the study drug regimen and through 30 days after the last dose of any agent in the study drug regimen.
Query!
Timepoint [11]
0
0
From the date of randomization through 30 days after the last dose of study drug up to end of study (up to approximately 9 years)
Query!
Secondary outcome [12]
0
0
Change From Baseline in Health-Related Quality of Life (HRQOL) Measured by European Organisation for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC-QLQ)-C30 Scale Total Score
Query!
Assessment method [12]
0
0
EORTC-QLQ-C30 scale was used to assess HRQOL in cancer participants and contains 30 items. Subscale with individual items include physical functioning items 1-5, role functioning items 6-7, emotional functioning items 21-24, cognitive functioning items 20, 25, social functioning items 26-27, quality of life items 29-30, fatigue items 10, 12, 18, nausea and vomiting items 14-15, pain items 9, 19, dyspnoea item 8, insomnia item 11, appetite loss item 13, constipation item 16, diarrhoea item 17, financial difficulties item 28. Raw scores were converted into scale scores ranging from 0 to 100. For the functional scales and the global health status scale, higher scores represent better HRQOL; whereas for the symptom scales lower scores represent better HRQOL. Positive change in functional and global health status scale indicated improvement; negative change for the symptom scales indicates improvement.
Query!
Timepoint [12]
0
0
Baseline to approximately 9 years
Query!
Secondary outcome [13]
0
0
Change From Baseline in HRQOL Measured by EORTC-QLQ-MY20 Scale
Query!
Assessment method [13]
0
0
EORTC QLQ-MY20 was a validated questionnaire to assess the overall quality of life in participants with multiple myeloma. The scale has 20 questions. Subscale and individual items include future perspective items 18-20, body image item 17, disease symptoms items 1-6, side effects of treatment items 7-16. Raw scores are averaged, and transformed to 0-100 scale, where higher score is better quality of life. Positive change indicates improvement.
Query!
Timepoint [13]
0
0
Baseline to approximately 9 years
Query!
Secondary outcome [14]
0
0
OS in High-risk Population Carrying Del(17p), t(4;14), or t(14;16) Mutations
Query!
Assessment method [14]
0
0
OS was defined as the time from the date of randomization to the date of death, as assessed in high-risk population carrying del(17p), t(4;14), or t(14;16) mutations. High risk category includes t(4;14), t(14;16), or del(17) abnormalities.
Query!
Timepoint [14]
0
0
From the date of randomization to death due to any cause (Up to approximately 9 years)
Query!
Secondary outcome [15]
0
0
PFS in High-risk Population Carrying Del(17p), t(4;14), or t(14;16) Mutations
Query!
Assessment method [15]
0
0
PFS was defined as the time from the date of randomization to the date of first documentation of progressive disease based on central laboratory results and IMWG criteria as evaluated by an independent review committee (IRC) or death due to any cause, whichever occurs first, as assessed in high-risk population carrying del(17p), t(4;14), or t(14;16) mutations.
Query!
Timepoint [15]
0
0
Up to approximately 9 years
Query!
Secondary outcome [16]
0
0
Percentage of Participants With MRD-Negative Status as Assessed by Flow Cytometry
Query!
Assessment method [16]
0
0
The absence of minimal residual disease (MRD negativity) was tested in all participants who achieve a CR and maintained it until Cycle 18, using bone marrow aspirates.
Query!
Timepoint [16]
0
0
Up to Cycle 18 (cycle length = 28 days)
Query!
Secondary outcome [17]
0
0
Time to Pain Progression
Query!
Assessment method [17]
0
0
Time to pain progression was assessed as the time from randomization to the date of initial progression classification. Pain progression was defined as the occurrence of 1 of the following and confirmed by 2 consecutive evaluations (To qualify as progression, the participant must have a BPI-SF worst pain score > 4 during pain progression): 1) a = 2 point and 30% increase from Baseline in BPI-SF worst pain score without an increase in analgesic use, or 2) a 25% or more increase in analgesic use from Baseline without a decrease in BPI-SF worst pain score from Baseline. Brief Pain Inventory - Short Form (m-BPI-SF) is a participant rated 11-point Likert rating scale ranged from 0 (no pain) to 10 (worst pain imaginable).
Query!
Timepoint [17]
0
0
Up to approximately 9 years
Query!
Secondary outcome [18]
0
0
Cmax: Maximum Plasma Concentration for Ixazomib
Query!
Assessment method [18]
0
0
Query!
Timepoint [18]
0
0
Cycle 1 Day 1: Post-dose at multiple timepoints up to 4 hours; Pre-dose at Cycle 1 Day 14, Cycles 2-3 Day 1 and Day 14, Cycles 4-11 Day 1 (Each cycle length = 28 days)
Query!
Secondary outcome [19]
0
0
Percentage of Participants With New or Worsening of Existing Skeletal-related Events (SREs)
Query!
Assessment method [19]
0
0
SRE is defined as new fractures [including vertebral compression fractures], irradiation of or surgery on bone, or spinal cord compression.
Query!
Timepoint [19]
0
0
From the date of randomization through 30 days after the last dose of study drug up to end of study (up to approximately 9 years)
Query!
Eligibility
Key inclusion criteria
1. Male or female participants 18 years or older diagnosed with Multiple Myeloma
according to standard criteria who have not received prior treatment for multiple
myeloma.
2. Participants for whom lenalidomide and dexamethasone treatment is appropriate and who
are not eligible for high-dose therapy followed by stem-cell transplantation (HDT-SCT)
for 1 or more of the following reasons:
- The participant is 65 years of age or older.
- The participant is less than 65 years of age but has significant comorbid
condition(s) that are, in the opinion of the investigator, likely to have a
negative impact on tolerability of HDT-SCT.
3. Measurable disease as specified in study protocol.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
5. Meet the clinical laboratories criteria as specified in the protocol.
6. Female participants who are post menopausal, surgically sterile, or agree to practice
2 effective methods of contraception or agree to practice true abstinence, and must
also agree to ongoing pregnancy testing; must also adhere to the guidelines of the
lenalidomide pregnancy prevention program.
7. Male participants who agree to practice effective barrier contraception or agree to
practice true abstinence AND must adhere to the guidelines of the lenalidomide
pregnancy prevention program.
8. Suitable venous access for the study-required blood sampling.
9. Must be able to take concurrent aspirin 70 mg to 325 mg daily (or enoxaparin if
aspirin allergic).
10. Voluntary written consent.
11. Participant is willing and able to adhere to the study visit schedule and other
protocol requirements.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Prior treatment for multiple myeloma with either standard of care treatment or
investigational regimen.
2. Diagnosed and treated for another malignancy within 5 years before randomization or
previously diagnosed with another malignancy and have any evidence of residual
disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type
are not excluded if they have undergone complete resection.
3. Inability or unwillingness to receive antithrombotic therapy.
4. Female participants who are lactating or pregnant.
5. Major surgery or radiotherapy within 14 days before randomization.
6. Infection requiring intravenous antibiotics within 14 days before the first dose of
study drug.
7. Central nervous system involvement.
8. Diagnosis of Waldenstrom's macroglobulinemia, polyneuropathy, organomegaly,
endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome, plasma cell
leukemia, primary amyloidosis, myelodysplastic syndrome, or myeloproliferative
syndrome.
9. Evidence of current uncontrolled cardiovascular conditions within 6 months prior to
randomization, including: Uncontrolled hypertension, cardiac arrhythmias, or
congestive heart failure; Unstable angina, or Myocardial infarction.
10. Systemic treatment with strong inhibitors of CYP1A2 (fluvoxamine, enoxacin,
ciprofloxacin), strong inhibitors of CYP3A (clarithromycin,
telithromycin,itraconazole, voriconazole, ketoconazole, nefazodone, posaconazole) or
strong CYP3A inducers (rifampin, rifapentine, rifabutin, carbamazepine, phenytoin,
phenobarbital), or use of Ginkgo biloba or St. John's wort within 14 days before
randomization in the study.
11. Active hepatitis B or C virus infection, or known human immunodeficiency virus (HIV)
positive.
12. Comorbid systemic illnesses or other severe concurrent disease which, in the judgment
of the investigator, would make the participant inappropriate for entry into this
study or interfere significantly with the proper assessment of safety and toxicity of
the prescribed regimens (e.g., peripheral neuropathy that is Grade 1 with pain or
Grade 2 or higher of any cause).
13. Psychiatric illness/social situation that would limit compliance with study
requirements.
14. Known allergy to any of the study medications.
15. Inability to swallow oral medication, inability or unwillingness to comply with the
drug administration requirements, or gastrointestinal (GI) procedure that could
interfere with the oral absorption or tolerance of treatment.
16. Treatment with any investigational products within 60 days before randomization.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/04/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
24/06/2022
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
705
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Florida
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Georgia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Hawaii
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Iowa
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Kentucky
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Louisiana
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Maryland
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Massachusetts
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Michigan
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Minnesota
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Missouri
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New Jersey
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
New Mexico
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
New York
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Ohio
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Oklahoma
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Oregon
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Pennsylvania
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
South Carolina
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Tennessee
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Texas
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Virginia
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Washington
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Brussels
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Namur
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Oost-Vlaanderen
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Vlaams Brabant
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
West-Vlaanderen
Query!
Country [35]
0
0
Belgium
Query!
State/province [35]
0
0
Bruges
Query!
Country [36]
0
0
Belgium
Query!
State/province [36]
0
0
Liege
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Alberta
Query!
Country [38]
0
0
Canada
Query!
State/province [38]
0
0
British Columbia
Query!
Country [39]
0
0
Canada
Query!
State/province [39]
0
0
New Brunswick
Query!
Country [40]
0
0
Canada
Query!
State/province [40]
0
0
Nova Scotia
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
France
Query!
State/province [43]
0
0
Alpes-Maritimes
Query!
Country [44]
0
0
France
Query!
State/province [44]
0
0
Bas-Rhin
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Finistere
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Haute-Vienne
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Herault
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Isere
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Loire-Atlantique
Query!
Country [50]
0
0
France
Query!
State/province [50]
0
0
Maine-et-Loire
Query!
Country [51]
0
0
France
Query!
State/province [51]
0
0
Marne
Query!
Country [52]
0
0
France
Query!
State/province [52]
0
0
Meurthe-et-Moselle
Query!
Country [53]
0
0
France
Query!
State/province [53]
0
0
Morbihan
Query!
Country [54]
0
0
France
Query!
State/province [54]
0
0
Nord
Query!
Country [55]
0
0
France
Query!
State/province [55]
0
0
Pas-de-Calais
Query!
Country [56]
0
0
France
Query!
State/province [56]
0
0
Rhone
Query!
Country [57]
0
0
France
Query!
State/province [57]
0
0
Seine-Maritime
Query!
Country [58]
0
0
France
Query!
State/province [58]
0
0
Vienne
Query!
Country [59]
0
0
France
Query!
State/province [59]
0
0
Amiens
Query!
Country [60]
0
0
France
Query!
State/province [60]
0
0
Bayonne
Query!
Country [61]
0
0
France
Query!
State/province [61]
0
0
Bordeaux
Query!
Country [62]
0
0
France
Query!
State/province [62]
0
0
Caen
Query!
Country [63]
0
0
France
Query!
State/province [63]
0
0
Chalon sur Saone
Query!
Country [64]
0
0
France
Query!
State/province [64]
0
0
Creteil
Query!
Country [65]
0
0
France
Query!
State/province [65]
0
0
Dunkerque
Query!
Country [66]
0
0
France
Query!
State/province [66]
0
0
La Roche sur Yon
Query!
Country [67]
0
0
France
Query!
State/province [67]
0
0
Le Chesnay
Query!
Country [68]
0
0
France
Query!
State/province [68]
0
0
Le Mans cedex 2
Query!
Country [69]
0
0
France
Query!
State/province [69]
0
0
Lille
Query!
Country [70]
0
0
France
Query!
State/province [70]
0
0
Montpellier cedex 5
Query!
Country [71]
0
0
France
Query!
State/province [71]
0
0
Mulhouse
Query!
Country [72]
0
0
France
Query!
State/province [72]
0
0
Paris
Query!
Country [73]
0
0
France
Query!
State/province [73]
0
0
Perigueux
Query!
Country [74]
0
0
France
Query!
State/province [74]
0
0
Pierre Benite
Query!
Country [75]
0
0
France
Query!
State/province [75]
0
0
Pontoise
Query!
Country [76]
0
0
France
Query!
State/province [76]
0
0
Rouen
Query!
Country [77]
0
0
France
Query!
State/province [77]
0
0
TOULOUSE Cedex 9
Query!
Country [78]
0
0
France
Query!
State/province [78]
0
0
Tours
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Gyeonggido
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Daegu
Query!
Country [81]
0
0
Korea, Republic of
Query!
State/province [81]
0
0
Daejeon
Query!
Country [82]
0
0
Korea, Republic of
Query!
State/province [82]
0
0
Incheon
Query!
Country [83]
0
0
Korea, Republic of
Query!
State/province [83]
0
0
Jeongnam
Query!
Country [84]
0
0
Korea, Republic of
Query!
State/province [84]
0
0
Seoul
Query!
Country [85]
0
0
New Zealand
Query!
State/province [85]
0
0
North Island
Query!
Country [86]
0
0
New Zealand
Query!
State/province [86]
0
0
South Island
Query!
Country [87]
0
0
New Zealand
Query!
State/province [87]
0
0
Hamilton
Query!
Country [88]
0
0
Russian Federation
Query!
State/province [88]
0
0
Ryazan
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Millennium Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to provide continued access to ixazomib and/or lenalidomide to
participants who are continuing to have clinical benefit and to continue collecting relevant
safety data to monitor safety in participants with Newly Diagnosed Multiple Myeloma (NDMM)
who are not eligible for stem cell transplant.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01850524
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Director Clinical Science
Query!
Address
0
0
Millennium Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01850524
Download to PDF